XML 36 R6.htm IDEA: XBRL DOCUMENT v2.4.0.8
CONDENSED CONSOLIDATED STATEMENT OF CASH FLOWS (USD $)
In Thousands, unless otherwise specified
 6 Months Ended 203 Months Ended
Jun. 30, 2013
Jun. 30, 2012
Jun. 30, 2013
Operating activities:      
Net loss $ (1,590) $ (6,532) $ (268,325)
Adjustments to reconcile net loss to net cash used in operating activities:      
Accretion of interest on notes payable, net of amortization of debt premium     100
Amortization of investment premiums, net     (2,297)
Change in valuation of liabilities measured at fair value (1,120) (140) (7,475)
Non-cash consideration associated with stock purchase agreement     423
Depreciation 36 30 12,651
Amortization of intangible assets     886
Fixed asset impairment     221
Unrealized foreign exchange (gains) losses     7,747
Deferred revenue     (98)
Compensation for warrants issued to non-employees     1,215
Gain on sale of patents (5,500)   (5,500)
Shares issued for IP rights     446
Loss (gain) on disposal of property, plant and equipment   (62) 38
Goodwill and intangibles impairment     7,934
Stock-based compensation 146 211 19,549
Provision for restructuring     1,779
Amortization of issuance costs of Preferred Ordinary 'C' shares     2,517
Transaction costs on sale of Economic Rights   33 33
Gain on termination of distribution agreements     (1,192)
Changes in operating assets and liabilities:      
Prepaid expenses and other assets (1,124) (307) (1,421)
Accounts payable and other current liabilities (1,530) (709) (5,075)
Net cash used in operating activities (10,682) (7,476) (235,844)
Investing activities:      
Purchase of ALIGN     (3,763)
Purchase of property, plant and equipment (92) (10) (8,941)
Minimum royalty payments received from termination of ALIGN license agreement 264   264
Proceeds from sale of patents 5,500   5,500
Proceeds from sale of property, plant and equipment   62 225
Purchase of short-term investments on deposit, net of maturities     (156,657)
Cash proceeds from redemption of short term securities     162,729
Net cash provided by (used in) investing activities 5,672 52 (643)
Financing activities:      
Payments of capital lease obligations     (3,719)
Proceeds from issuance of ordinary and preferred ordinary shares, net of issuance costs     121,678
Proceeds from issuance of common stock and warrants, net of issuance costs 22,495 2,886 118,047
Proceeds from the exercise of stock options and warrants, net of issuance costs   34 267
Payment of preferred stock dividend (192)   (2,090)
Repayment of government loan     (455)
Government loan received     414
Loan received from Cyclacel Group plc     9,103
Proceeds of committable loan notes issued from shareholders     8,883
Loans received from shareholders     1,645
Cash and cash equivalents assumed on stock purchase of Xcyte     17,915
Costs associated with stock purchase     (1,951)
Net cash provided by financing activities 22,303 2,920 269,737
Effect of exchange rate changes on cash and cash equivalents (37) 19 418
Net increase (decrease) in cash and cash equivalents 17,256 (4,485) 33,668
Cash and cash equivalents, beginning of period 16,412 24,449  
Cash and cash equivalents, end of period 33,668 19,964 33,668
Cash received during the period for:      
Interest 5 8 11,761
Taxes     18,772
Cash paid during the period for:      
Interest     (1,914)
Taxes     (166)
Schedule of non-cash transactions:      
Acquisitions of equipment purchased through capital leases     3,470
Issuance of shares of common stock in connection with license agreements     592
Issuance of Ordinary shares on conversion of bridging loan     1,638
Issuance of Preferred Ordinary 'C' shares on conversion of secured convertible loan notes and accrued interest     8,893
Issuance of Ordinary shares in lieu of cash bonus 181   345
Issuance of other long term payable on ALIGN acquisition     $ 1,122